Novel T-Cell Immunotherapies Market Exclusive Report with Detailed Study Analysis

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on "Global Novel T-Cell Immunotherapies Market- Industry Trends, Clinical Trial/Pipeline Analysis, Funding Analysis, Industry Competition Analysis, and Revenue Forecast To 2031."

The Novel T-Cell Immunotherapies Market is expected to grow at a 38.0 % CAGR during the forecast period for 2023-2031.ord a promising CAGR of 47% during the period of 2022-2031.

Request for Free Sample Pages: https://www.insightaceanalytic.com/request-sample/1020

T-cell immunotherapy reprograms an individual's immune cells to be more effective against malignancy. T-cell transfer therapy is an adoptive cell therapy known as immune and immunotherapy. Novel T-cell therapies include T-cells, activated T-cells, Tregs, virus-driven T-cells, and T-cell vaccines. In clinical trials, gamma delta T cell therapies outperformed conventional cancer therapies regarding cancer cell-targeting efficacy and specificity. The treatment requires a brief duration with no aggressive chemotherapy. T-cell immunotherapy is a new and swiftly developing area of oncology. T-cell therapies have emerged as a promising option among current targeted anti-cancer therapies due to their high target specificity, the potential for customization, the capacity to generate immunological memory and common adverse effects.

The rising prevalence of chronic diseases will drive the market growth for novel T-cell immunotherapies over the forecast period. The development of the Novel T-Cell Immunotherapies Market is anticipated to be bolstered by many strategic agreements between relevant therapy developers and research institutes to innovate therapies. In the upcoming years, opportunities will arise due to the rising demand for cell and gene therapies, the high mortality rates, and the increasing number of clinical trials. In addition, the government is promoting health consciousness among the rising elderly population and cancer patients.

However, the high investment required for therapy development, the absence of standard therapy protocols, and the need for more qualified professionals restrict market expansion.

Enquiry Before Buying: https://www.insightaceanalytic.com/enquiry-before-buying/1020

Due to rising awareness about cell therapies, increasing government investments in the research and development of cell therapies to treat various diseases, and high demand for novel therapies, North America is the most lucrative region for this market. On the other hand, Europe is anticipated to dominate this market due to the biopharmaceutical industry's advancements and the continent's high cancer prevalence. In addition, the Asia-Pacific market is expected to expand quickly due to the expansion of cell therapy manufacturing industries and the rise in chronic disease prevalence.

Some of the key players in the novel T-cell immunotherapies market are Atara Biotherapeutics, AlloVir, Eureka Therapeutics, Eutilex, NexImmune, OSE Immunotherapeutics, Tevogen Bio, WindMIL Therapeutics, GammaDelta Therapeutics Limited, Acepodia, Adaptate Therapeutics, Adicet, Cytomed Therapeutics, Gadeta, IN8bio, Kiromic Biopharma, Lava Therapeutics, Takeda Pharmaceuticals, TC Biopharm, ImCheck Therapeutics, Expression Therapeutics LLC, Triumvira Immunologics, PureTech Health, PhosphoGam, Caladrius Biosciences, Eli Lilly and Company, Miltenyi Biotec, Sangamo Therapeutics (TxCell), Cellenkos Inc., Pfizer Inc., PolTREG S.A.., Parvus Therapeutics, ILTOO Pharma, Philogen S.p.A., TRACT Therapeutics, Inc., REGiMMUNE Co, Ltd., Roche, Celgene, AHEAD THERAPEUTICS S.L., and Other Prominent Players.

Innovative therapies, partnerships, collaborations, and agreements are a priority for leading manufacturers in this industry. Additionally, the increasing public awareness of cell treatments will help to drive market expansion.

Get Specific Chapter/Information From The Report:https://www.insightaceanalytic.com/customisation/1020

Recent Key Developments:
• In May 2022, Harpoon Therapeutics announced a clinical supply agreement with F. Hoffmann-La Roche Ltd (Roche) to supply atezolizumab (Tecentriq®) for use in the clinical development program. Under this agreement, Harpoon is the sponsor of the anticipated clinical trials, and Roche will supply atezolizumab.
• In Oct 2021, Takeda Pharmaceutical Company Limited announced the exercise to acquire GammaDelta Therapeutics Limited. Takeda will obtain GammaDelta's allogeneic variable delta 1 (V1) gamma-delta (γδ) T cell therapy platforms, including both blood-derived and tissue-derived platforms and early-stage cell therapy programmes, through the acquisition.
• In Aug 2021, Trillium Therapeutics Inc. and Pfizer Inc. announced that the two companies have entered into a binding agreement under which Pfizer would acquire Trillium. With the inclusion of next-generation, experimental immuno-therapeutics for haematological malignancies, the proposed purchase improves Pfizer's position as the market leader in oncology.
• In Mar 2020, AlloVir, a clinical-stage T-cell immunotherapy company, collaborated with Baylor College of Medicine to develop allogeneic, virus-specific T-cell therapy to combat COVID-19. Also, in September 2020, AlloVir Announced the FDA Clearance of Investigational New Drug Application (IND) for ALVR109 (an allogeneic, off-the-shelf virus-specific T cell therapy candidate designed to target SARS-CoV-2) for the Treatment of High-Risk COVID-19 Patients.

Market Segments
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Type of T-cell Therapy
• Activated T-cells
• Virus Driven T-cells
• Tregs
• γδ T-cells
• T-cell vaccines
• NK T-cells
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Disease Indication
• Lung cancer
• Breast Cancer
• Cytomegalovirus Infection
• Glioblastoma
• Hepatocellular Carcinoma
• Acute Myeloid Leukemia
• Ovarian Cancer
• Type 1 Diabetes Mellitus
• Sarcoma
• HIV infections
• Pancreatic Cancer
• Others
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

North America novel T-cell immunotherapies market revenue (US$ Million) by Country, 2022 to 2030
• U.S.
• Canada
Europe novel T-cell immunotherapies market revenue (US$ Million) by Country, 2022 to 2030
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific novel T-cell immunotherapies market revenue (US$ Million) by Country, 2022 to 2030
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America novel T-cell immunotherapies market revenue (US$ Million) by Country, 2022 to 2030
• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa novel T-cell immunotherapies market revenue (US$ Million) by Country, 2022 to 2030
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Why should buy this report:
> To receive a comprehensive clinical trial/pipeline analysis of the prospects for global novel T-cell immunotherapies market
> To receive industry overview and future trends of global novel T-cell immunotherapies market
> To analyze the novel T-cell immunotherapies market drivers and challenges
> To get information on the novel T-cell immunotherapies market size value (US$ Mn) forecast till 2030
> Major Investments, Mergers & Acquisition in global novel T-cell immunotherapies market industry

For More Information: https://www.insightaceanalytic.com/report/global-novel-t-cell-immunotherapies-market/1020

Other Related Reports Published by InsightAce Analytic:
Global CAR T-Cell Therapy For Multiple Myeloma Market
Global Regulatory T-Cell (Tregs) Therapies Market
Global Allogeneic Cell Therapy Manufacturing Market
Global Immuno-Oncology Cell Therapy Market

Corporate Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
loaction icon
Sales Office (U.S.) :
344 Grove St Unit #967 Jersey City, NJ 07302
email iconinfo@insightaceanalytic.com
call icon
North America:
+1 551 226 6109
Asia:
+91 79 72967118

Contact Us:
Dhanraj Zurange
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

This release was published on openPR.